Mexico HIV Therapeutics Market Analysis Report [2022-30]

Mexico HIV Therapeutics Market Analysis

$ 3999

The Mexico HIV therapeutics market is expected to reach $xx Mn by 2030, up from $206.4 Mn in 2022, with a CAGR of xx% from 2022 to 2030. Local Players such as PiSA Farmaceutica, Laboratorios Liomont, and Silanes Laboratories dominate the HIV therapeutics market in Mexico. The government policies, funding, and initiatives by international organizations to manage HIV infections in the country propel the market. The HIV therapeutics market in Mexico is divided into four segments: type, product, geography, end user, and distribution channel.

ID: IN10MXPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico AUTHOR: Dr. Vishwa Modhia

Buy Now

Mexico HIV Therapeutics Market Analysis Summary

Mexico is a country in North America that shares borders with Belize, the United States, and Guatemala. The Mexico HIV therapeutics market is expected to be worth $xx Mn by 2030, up from $206.4 Mn in 2022, with a CAGR of xx % from 2022 to 2030.

Mexico ranked 72nd in the world in terms of adult HIV/AIDS prevalence in 2020, with 3,40,000 HIV cases. According to the most recent WHO data, HIV/AIDS deaths in Mexico reached 4,128 in 2020, accounting for 0.67 % of deaths.

Mexico ranks 90th in the world with an age-adjusted death rate of 3.23 per 100,000 population. The Mexican Movement for Positive Citizenship (MMPC) aids in the fight against HIV/AIDS in Mexico by assisting those who are "invisible to society." Mexico spent 6.2% of its GDP on health care.

mexico HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers

In Mexico, the fight against HIV/AIDS begins with the United Nations PrEP programme. The programme was awarded $26 Mn in HIV treatment funding to help 7,500 at-risk people in Mexico, Brazil, and Peru until 2020. In Mexico, the PrEP programme was open to provide free treatments to up to 3,000 people in four Mexican cities: Puerto Vallarta, Mexico City, Merida, and Guadalajara. In addition, patients were given free STD testing, counselling, and condoms. These factors may entice new entrants into the Mexican HIV therapeutics market.

Market Restraint

The stigma associated with positive HIV status has a significant impact on HIV testing and treatment. HIV prevalence is particularly high among gay men, prisoners, transgender people, and sex workers in Mexico. Because of homophobia and machismo culture, "sex between men is highly stigmatised. These factors could discourage new entrants into the Mexican HIV therapeutics market.

Competitive Landscape

Key Players

Silanes Laboratories (MEX)
Laboratorios Liomont (MEX)
PiSA Farmaceutica (MEX)
Rimsa (MEX)
Laboratorios Kendrick (MEX)
ViiV Healthcare
Bristol Myers Squibb
Merck & Co.
Gilead Sciences

Healthcare Regulations and Reimbursement Policies

The Federal Commission for the Protection Against Sanitary Risk regulates HIV therapeutics in Mexico (COFEPRIS). COFEPRIS is in charge of overseeing the importation, manufacture, marketing, and distribution of all pharmaceuticals and medical devices, including those used to treat HIV. All HIV therapeutics must meet specific regulatory requirements to be registered by COFEPRIS, including clinical trials and testing for safety and efficacy, good manufacturing practices, and labelling requirements.

HIV therapeutics are reimbursed in Mexico through the government's social security system, the Mexican Institute of Social Security (IMSS), and the Popular Health Insurance System (Seguro Popular). These programmes aim to provide people living with HIV in Mexico, regardless of socioeconomic status, with access to affordable and effective HIV therapeutics. IMSS is a government-sponsored health insurance programme that covers employees and their dependents in the formal sector.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.